The aim of the present study was to evaluate whether or not CSF AT III is an independent biomarker of lymphoma CNS lesions or a marker of blood–brain barrier leakage, and whether it could be used to find patients with systemic lymphoma and subclinical CNS disease. Here, SERPINC1 is linked to lymphoma.